Platinum Sponsors
Eisai
Eisai is dedicated to giving first thought to patients and their families through our human health care (hhc) philosophy. Our dedication to patients drives our efforts to innovate oncology medicines. Our mission is to significantly contribute to society in an ethical, compliant and sustainable way by embodying our hhc philosophy. Eisai is a platinum sponsor of the ESMO Gynae Congress 2022. EMEA-ONC-22-00039 | April 2022
- Onsite booth number: 5
- Virtual booth
GSK
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
- Onsite booth number: 4
- Virtual booth
Silver Sponsors
Alkermes
Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia, bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer.
- Onsite booth number: 6
- Virtual booth
Seagen International GmbH
Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors.
- Onsite booth number: 2
- Virtual booth
Bronze Sponsor
Immunogen
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Society
ESMO
With more than 25,000 members representing professionals from 160+ countries, ESMO is the leading professional organisation for medical oncology and the society of reference for oncology education and information. Driven by the determination to secure the best possible outcomes for patients, ESMO stands by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.
- Onsite booth number: 3
- Virtual Booth